Inflammasome activation promotes venous thrombosis through pyroptosis

Yan Zhang,1,2 Jian Cui,3 Guoying Zhang,1 Congqing Wu,1 Ahmed Abdel-Latif,1 Susan S. Smyth,1,4 Toshihiko Shiroishi,5 Nigel Mackman,6 Yinan Wei,3 Min Tao,2 and Zhenyu Li1

1Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Lexington, KY; 2Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China; 3Department of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY; 4Veterans Affairs Medical Center, Lexington, KY; 5RIKEN BioResource Research Center, Tsukuba, Ibaraki, Japan; and 6Division of Hematology, Department of Medicine, UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

Crosstalk between coagulation and innate immunity contributes to the progression of many diseases, including infection and cardiovascular disease. Venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis (DVT), is among the most common causes of cardiovascular death. Here, we show that inflammasome activation and subsequent pyroptosis play an important role in the development of venous thrombosis. Using a flow restriction–induced mouse venous thrombosis model in the inferior vena cava (IVC), we show that deficiency of caspase-1, but not caspase-11, protected against flow restriction–induced thrombosis. Interleukin-1β expression increased in the IVC following ligation, indicating that inflammasome is activated during injury. Deficiency of gasdermin D (GSDMD), an essential mediator of pyroptosis, protected against restriction-induced venous thrombosis. After induction of venous thrombosis, fibrin was deposited in the veins of wild-type mice, as detected using immunoblotting with a monoclonal antibody that specifically recognizes mouse fibrin, but not in the caspase-1–deficient or GSDMD-deficient mice. Depletion of macrophages by gadolinium chloride or deficiency of tissue factor also protected against venous thrombosis. Our data reveal that tissue factor released from pyroptotic monocytes and macrophages following inflammasome activation triggers thrombosis.

Introduction

Venous thromboembolism (VTE) is a leading cause of cardiovascular death,1 affecting 300,000 to 600,000 individuals (1 to 2 per 1000) each year in the United States.2-4 The initiation of venous thrombus formation is a multifactorial process that involves a complex cascade of events. Endothelial activation and recruitment of immune cells, including monocytes and neutrophils, are observed in deep vein thrombosis (DVT).5 It appears that crosstalk between monocytes, neutrophils, and platelets is responsible for the initiation and amplification of DVT.5 Both platelets and endothelium play an important role in venous thrombosis.5 Besides directly participating in thrombosis, platelets contribute to DVT through several other mechanisms, including supporting coagulation, forming platelet-leukocyte aggregates, thereby supporting leukocyte recruitment, promoting neutrophil extracellular traps formation, etc.6

Venous thrombi are rich in fibrin and red blood cells.7 Hypercoagulable state is thought to be one of the major risk factors for the formation of venous thrombi.8 Accordingly, tissue factor (TF) derived from
myeloid leukocytes is a central initiator of DVT. It is known that blood flow restriction or stasis, and subsequent local hypoxia, is a major factor driving DVT. Hypoxia can induce expression of the inflammasome NLRP3 and caspase-1. Importantly, expression of caspase-1 is elevated in patients with VTE, suggesting a potential role of the inflammasome in DVT. We recently showed that TF released from monocytes and macrophages following inflammasome activation triggers coagulation during sepsis. In this study, we used caspase-1-deficient mice to demonstrate that inflammasome activation plays an important role in the development of DVT. Development of DVT was also inhibited by deficiency of gasdermin D (GSDMD) and TF, and monocyte depletion. Our findings identify a novel mechanism of DVT, which is through TF released from pyroptotic monocytes and macrophages following inflammasome activation.

**Methods**

**Mice**

Wild-type (WT) C57BL/6J, Casp1−/−, Casp11−/−, Gsdmd−/−, B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J Cre transgenic mice, TF floxed mice, and WT littermates were housed in the University of Kentucky Animal Care Facility, following institutional and National Institutes of Health guidelines after approval by the Institutional Animal Care and Use Committee. Male mice at 8 to 12 weeks were used in all experiments. Inducible TF-deficient mice were generated by breeding the B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J Cre transgenic mice with TF floxed mice. CreER2-recombinase expression for removal of TF was induced by intraperitoneal injections of tamoxifen (Sigma) at 100 mg/kg per day for 5 consecutive days at 4 to 5 weeks of age, and subsequent experiments were carried out at 5 weeks postinduction. WT littermates were also treated with tamoxifen.

**Induction of flow restriction model in mice**

The model of DVT was induced using a stenosis model in inferior vena cava (IVC). In brief, mice were anesthetized and placed in a supine position. The abdomen was opened along the midline, and the intestines were exteriorized gently. Warmed saline was applied to intestine regularly during the surgery to prevent drying out. The IVC was gently separated from aorta and then was ligated under the left renal vein with a 7-0 polypropylene suture over a spacer (30-gauge needle [0.3 mm × 25 mm]). After that, the spacer was removed to create a 90% stenosis without endothelial disruption. All visible side branches were ligated completely. Finally, the intestines were returned to the peritoneal cavity; the peritoneum was closed with staples. After 48 hours, thrombi were harvested for measurement.

**Fibrin extraction for immunoblotting analysis**

Thrombi were homogenized in 10 volumes (mg/mL) of the tissue protein extraction reagent (T-PER; Thermo, Cat. no. 78510) containing protease cocktail inhibitor (Sigma, Cat. no. P8340) and phenylmethylsulfonyl fluoride. After centrifugation at 10,000g for 10 minutes, the supernatant was collected for β-actin detection. The pellet was homogenized in 3 M urea and vortexed for 2 hours at 37°C. After centrifugation at 14,000g for 15 minutes, the pellet was resuspended in sodium dodecyl sulfate (SDS) buffer and vortexed at 65°C for 30 minutes for fibrin detection.

**Western blot**

For detection of fibrin and interleukin (IL)-1β by western blot, tissue homogenates were analyzed using SDS–polyacrylamide gel electrophoresis on 4% to ~15% gradient gels, immunoblotted using antifibrin (59DB) antibody at 1 μg/mL or anti–IL-1β polyclonal antibody (1 μg/mL, GeneTex, GTX74034). For detection of TF by western blot, brain tissue homogenates were analyzed using SDS–polyacrylamide gel electrophoresis on 4% to 15% gradient gels, immunoblotted using anti-TF antibody at 0.5 μg/mL (Abcam, ab189483).

**Monocyte and macrophage depletion**

Gadolinium (III) chloride (GdCl₃) (Sigma, Cat. no. G7532) was used to deplete peripheral monocytes, GdCl₃ (45 mg/kg) was administrated retroorbitaly 24 hours before IVC ligation.

**Statistical analysis**

Nonparametric data (weight and length of thrombus) were analyzed using the Mann-Whitney U test (2-sided). Parametric results (monocyte depletion and neutrophil counts) were analyzed using 2-tailed Student t test. DVT incidence was analyzed by χ² analysis. P < .05 was considered statistically significant. All statistical analyses were conducted on biological replicates in GraphPad Prism 7.

**Results and discussion**

**Deficiency of caspase-1 protects against venous thrombosis following IVC ligation**

To investigate the role of inflammasome activation in venous thrombosis development, we compared formation of venous thrombosis between WT and caspase-1–deficient mice utilizing an IVC stenosis model to induce DVT. Forty-eight hours after IVC ligation, 75.0% of the WT mice developed venous thrombosis (Figure 1A). In contrast, only 35.3% of the caspase-1–deficient mice developed venous thrombosis. The weight and length of thrombi were also reduced in the caspase-1–deficient mice (Figure 1B-D). Although activation of the canonical pathway of inflammasome leads to caspase-1 cleavage and activation, activation of the noncanonical pathway of inflammasome results in cleavage and activation of caspase-11. To determine whether the noncanonical inflammasome pathway is involved in venous thrombosis, we examined venous thrombosis in caspase-11–deficient mice. Although the incidence of thrombosis in the caspase-11–deficient mice is slightly lower than in WT mice (50.0% for caspase-11–deficient mice vs 64.3% for WT), the difference did not reach statistical significance (Figure 1E). Accordingly, the weight and length of thrombi were not affected by caspase-11 deficiency (Figure 1F-G). Thus, the noncanonical inflammasome pathway does not play a major role in venous thrombosis. In agreement with the contribution of caspase-1 to venous thrombosis, IL-1β was detected in the thrombi of WT mice and caspase-11–deficient mice, but not in the caspase-1–deficient mice (Figure 1H).

**Inflammasome activation enhances venous thrombus formation through pyroptosis**

Inflammasome activation leads to release of inflammatory cytokines IL-1β and -18, as well as a GSDMD-mediated programmed necrotic cell death, pyroptosis. To determine whether pyroptosis contributes to the development of DVT, we examined flow restriction–induced venous thrombosis in the GSDMD-deficient mice.
of GSDMD-deficient mice, 30.0% produced thrombi, whereas 66.7% of the WT littermates developed thrombi (Figure 2A). Both thrombus weight and length in the IVC following flow restriction were reduced in the GSDMD-deficient mice (Figure 2B-D). These data demonstrate that pyroptosis is required for flow restriction–induced venous thrombosis. Platelets play a key role in arterial thrombosis. To determine whether inflammasome activation may also contribute to arterial thrombosis, we observed the effect of inflammasome and pyroptosis on platelet aggregation and FeCl₃-induced carotid artery thrombosis. Our data indicate that FeCl₃-induced carotid artery thrombosis was not affected by deficiency of caspase-1 or GSDMD (supplemental Figure 1A). Accordingly, platelet aggregation in response to thrombin or collagen was not affected by deficiency of caspase-1 or GSDMD (supplemental Figure 1B-C).

**Inflammasome activation increases TF release in venous thrombosis**

A venous thrombus is rich in fibrin. By using western blot with a monoclonal antibody specifically recognizing mouse fibrin,¹⁵ we detected fibrin formation in the venous thrombus milieu of WT and caspase-1 or GSDMD-deficient mice following IVC ligation.²⁶ Our data indicate that normalized fibrin concentration was less in thrombus tissues from the caspase-1− or GSDMD-deficient mice than thrombus tissues from WT mice (Figure 2E). In contrast, deficiency of caspase-11 had no impact on fibrin concentration in the thrombus tissues (Figure 2F). Previous studies have shown that TF derived from myeloid leukocytes plays an important role in the development of DVT.⁵ We hypothesized that TF released from pyroptotic monocytes and macrophages may trigger venous thrombosis. Indeed, flow restriction–induced venous thrombosis was markedly inhibited in inducible whole-body TF-deficient mice (supplemental Figure 2). Flow restriction–induced venous thrombosis was also diminished in mice in which monocytes and macrophages were pre-depleted by administration of GdCl₃ (supplemental Figure 3; Figure 2G-I). Depletion of monocytes and macrophages by GdCl₃ did not affect neutrophil counts in peripheral blood and the function of neutrophil to form neutrophil extracellular traps (supplemental Figure 4). These data demonstrate that TF from monocytes and macrophages plays a key role in venous thrombosis.
Our results demonstrate that TF released from pyroptotic macrophages plays an important role in venous thrombosis and thus uncovers the mechanisms linking inflammation and thrombosis. Considering the risks of the anticoagulant treatment of venous thrombosis, strategies specifically targeting inflammasome activation and pyroptosis may lead to the development of novel therapeutics against venous thrombosis.

Acknowledgments

The authors acknowledge fibrin antibodies provided by Hartmut Weiler at Medical College of Wisconsin and Rodney M. Camire at the University of Pennsylvania.

This work was supported by grants K99HL145117 (C.W., who is a K99 awardee); National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) grant R01 HL124266 (A.A.-L.); National Science Foundation grant CHE-1709381 (Y.W.), NIH/National Institute of Allergy and Infectious Diseases grants R56 AI137020 (Y.W.), R21 AI142663 (Y.W.), NIH/NHLBI grant R01 HL142640 (Y.W.), NIH/National Institute of General Medical Sciences (NIGMS) grants R01 GM132443 (Y.W.); and NIH/NHLBI R01 HL146744 (Z.L.), R01 HL142640 (Z.L.), and NIH/NIGMS R01 GM132443 (Z.L.).

Authorship

Contribution: Y.Z., M.T., and Z.L. designed and performed the experiments and wrote the manuscript, assisted by G.Z., J.C., C.W., A.A.-L., S.S.S., N.M., Y.W., who contributed to manuscript preparation; T.S. and N.M. provided mice and discussed the experiments; and all authors discussed the results and commented on the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: C.W., 0000-0001-7725-7881; A.A.-L., 0000-0002-8178-7102.

Correspondence: Zhenyu Li, University of Kentucky, 741 South Limestone St, BBSRB, Room 351, Lexington, KY 40536; e-mail: zhenyuli08@uky.edu.
References

1. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. *Circulation*. 2011;123(4):e18-e209.

2. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. *Am J Prev Med*. 2010;38(4 Suppl):S495-S501.

3. Heit JA. The epidemiology of venous thromboembolism in the community. *Arterioscler Thromb Vasc Biol*. 2008;28(3):370-372.

4. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis*. 2016;41(1):3-14.

5. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. *J Exp Med*. 2012;209(4):819-835.

6. Schulz C, Engelmann B, Massberg S. Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. *J Thromb Haemost*. 2013;11(Suppl 1):233-241.

7. Aleman MM, Walton BL, Byrnes JR, Wolberg AS. Fibrinogen and red blood cells in venous thrombosis. *Thromb Res*. 2014;133(Suppl 1):S38-S40.

8. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. *Blood Transfus*. 2011;9(2):120-138.

9. Hodkinson PD, Hunt BJ, Parmar K, Ernsting J. Is mild normobaric hypoxia a risk factor for venous thromboembolism? *J Thromb Haemost*. 2003;1(10):2131-2133.

10. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. *Thromb Res*. 2019;181:77-83.

11. Brill A, Suidan GL, Wagner DD. Hypoxia, such as encountered at high altitude, promotes deep vein thrombosis in mice. *J Thromb Haemost*. 2013;11(9):1773-1775.

12. Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: what is the link? *Annu Rev Physiol*. 2011;73(1):527-545.

13. Gupta N, Sahu A, Prabhakar A, et al. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. *Proc Natl Acad Sci USA*. 2017;114(18):4763-4768.

14. Wu C, Lu W, Zhang Y, et al. Inflammasome activation triggers blood clotting and host death through pyroptosis. *Immunity*. 2019;50(6):1401-1411.e4.

15. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. *Science*. 1983;222(4628):1129-1132.

16. McKenzie CG, Kim M, Singh TK, Milev Y, Freedman J, Semple JW. Peripheral blood monocyte-derived chemokine blockade prevents murine transfusion-related acute lung injury (TRALI). *Blood*. 2014;123(22):3498-3503.

17. Amadio P, Tarantino E, Sandrini L, Tremoli E, Barbieri SS. Prostaglandin-endoperoxide synthase-2 deletion affects the natural trafficking of Annexin A2 in monocytes and favours venous thrombosis in mice. *Thromb Haemost*. 2017;117(8):1486-1497.

18. Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. 2015;526(7575):666-671.

19. Haggar JA, Powell DA, Aschou Y, Ernst RK, Miao EA. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. *Science*. 2013;341(6151):1250-1253.

20. Kayagaki N, Wong MT, Stowe IB, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. *Science*. 2013;341(6151):1246-1249.

21. Shi J, Zhao Y, Wang Y, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. *Nature*. 2014;514(7521):187-192.

22. Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature*. 2015;526(7575):660-665.

23. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. *Trends Biochem Sci*. 2017;42(4):245-254.

24. Fujii T, Tamura M, Tanaka S, et al. Gasdermin D (Gsdmd) is dispensable for mouse intestinal epithelium development. *Genesis*. 2008;46(8):418-423.

25. Yadav V, Chi L, Zhao R, et al. Ectonucleotidase tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1β-driven venous thrombosis. *J Clin Invest*. 2018;129(7):2872-2877.